Asset
CAMIDANLUMAB TESIRINE
ADC THERAPEUTICS SA COMMON SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02432235 | phase1 | completed | 2015-10-05 | 2019-10-24 | ADC Therapeutics S.A. | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
| NCT02588092 | phase1 | terminated | 2016-02-01 | 2018-08-29 | ADC Therapeutics S.A. | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) |
| NCT03621982 | phase1 | terminated | 2018-11-09 | 2022-12-14 | ADC Therapeutics S.A. | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors |
| NCT04052997 | phase2 | completed | 2019-09-13 | 2023-01-19 | ADC Therapeutics S.A. | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma |
FDA applications (0)
This company has no applications containing this asset.